Response to trametinib treatment in progressive pediatric low-grade glioma patients

ConclusionsTrametinib was an active and feasible treatment for progressive pLGG leading to disease control in all patients. However, treatment related toxicity interfered with treatment in individual patients, and disease control after MEKi withdrawal was not sustained in a fraction of patients. Our data support in-class efficacy of MEKi in pLGGs and necessity for upfront randomized testing of trametinib against current standard chemotherapy regimens.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research